Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 183

1.

Impact of the duration of antiviral prophylaxis on rates of varicella-zoster virus reactivation disease in autologous hematopoietic cell transplantation recipients.

Truong Q, Veltri L, Kanate AS, Hu Y, Craig M, Hamadani M, Cumpston A.

Ann Hematol. 2014 Apr;93(4):677-82. doi: 10.1007/s00277-013-1913-z. Epub 2013 Oct 6.

PMID:
24097085
2.

Onset and complications of varicella zoster reactivation in the autologous hematopoietic cell transplant population.

Rogers JE, Cumpston A, Newton M, Craig M.

Transpl Infect Dis. 2011 Oct;13(5):480-4. doi: 10.1111/j.1399-3062.2011.00655.x. Epub 2011 May 27.

PMID:
21615848
3.

Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation.

Asano-Mori Y, Kanda Y, Oshima K, Kako S, Shinohara A, Nakasone H, Sato H, Watanabe T, Hosoya N, Izutsu K, Asai T, Hangaishi A, Motokura T, Chiba S, Kurokawa M.

Am J Hematol. 2008 Jun;83(6):472-6. doi: 10.1002/ajh.21152.

4.

Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation.

Kanda Y, Mineishi S, Saito T, Saito A, Yamada S, Ohnishi M, Chizuka A, Niiya H, Suenaga K, Nakai K, Takeuchi T, Makimoto A, Tanosaki R, Kami M, Tanaka Y, Fujita S, Watanabe T, Kobayashi Y, Tobinai K, Takaue Y.

Bone Marrow Transplant. 2001 Oct;28(7):689-92.

5.

Varicella zoster virus infection after allogeneic hematopoietic cell transplantation in children using a relatively short duration of acyclovir prophylaxis: A retrospective study.

Han SB, Kim SK, Lee JW, Lee DG, Chung NG, Jeong DC, Cho B, Kang JH.

Medicine (Baltimore). 2017 Apr;96(14):e6546. doi: 10.1097/MD.0000000000006546.

6.

Varicella-zoster reactivation after allogeneic stem cell transplantation without routine prophylaxis--the incidence remains high.

Blennow O, Fjaertoft G, Winiarski J, Ljungman P, Mattsson J, Remberger M.

Biol Blood Marrow Transplant. 2014 Oct;20(10):1646-9. doi: 10.1016/j.bbmt.2014.06.002. Epub 2014 Jun 7.

7.

Incidence and risk of postherpetic neuralgia after varicella zoster virus infection in hematopoietic cell transplantation recipients: Hokkaido Hematology Study Group.

Onozawa M, Hashino S, Haseyama Y, Hirayama Y, Iizuka S, Ishida T, Kaneda M, Kobayashi H, Kobayashi R, Koda K, Kurosawa M, Masauji N, Matsunaga T, Mori A, Mukai M, Nishio M, Noto S, Ota S, Sakai H, Suzuki N, Takahashi T, Tanaka J, Torimoto Y, Yoshida M, Fukuhara T.

Biol Blood Marrow Transplant. 2009 Jun;15(6):724-9. doi: 10.1016/j.bbmt.2009.03.003.

8.
9.

The effect of low-dose aciclovir on reactivation of varicella zoster virus after allogeneic haemopoietic stem cell transplantation.

Thomson KJ, Hart DP, Banerjee L, Ward KN, Peggs KS, Mackinnon S.

Bone Marrow Transplant. 2005 Jun;35(11):1065-9.

PMID:
15806119
10.

Predicting risk factors for varicella zoster virus infection and postherpetic neuralgia after hematopoietic cell transplantation using ordered logistic regression analysis.

Kanbayashi Y, Matsumoto Y, Kuroda J, Kobayashi T, Horiike S, Hosokawa T, Taniwaki M.

Ann Hematol. 2017 Feb;96(2):311-315. doi: 10.1007/s00277-016-2883-8. Epub 2016 Nov 28.

PMID:
27896415
11.

Daily 500 mg valacyclovir is effective for prevention of Varicella zoster virus reactivation in patients with multiple myeloma treated with bortezomib.

Fukushima T, Sato T, Nakamura T, Iwao H, Nakajima A, Miki M, Sakai T, Kawanami T, Sawaki T, Fujita Y, Tanaka M, Masaki Y, Okazaki T, Nakajima H, Motoo Y, Umehara H.

Anticancer Res. 2012 Dec;32(12):5437-40.

PMID:
23225448
12.
13.

Low-dose acyclovir prophylaxis for the prevention of herpes simplex virus and varicella zoster virus diseases after autologous hematopoietic stem cell transplantation.

Kawamura K, Hayakawa J, Akahoshi Y, Harada N, Nakano H, Kameda K, Ugai T, Wada H, Yamasaki R, Ishihara Y, Sakamoto K, Ashizawa M, Sato M, Terasako-Saito K, Kimura S, Kikuchi M, Nakasone H, Yamazaki R, Kanda J, Kako S, Tanihara A, Nishida J, Kanda Y.

Int J Hematol. 2015 Aug;102(2):230-7. doi: 10.1007/s12185-015-1810-4. Epub 2015 May 20.

PMID:
25990803
14.

Acyclovir prophylaxis against varicella zoster virus reactivation in multiple myeloma patients treated with bortezomib-based therapies: a retrospective analysis of 100 patients.

Swaika A, Paulus A, Miller KC, Sher T, Almyroudis NG, Ball D, Wood M, Masood A, Lee K, Chanan-Khan AA.

J Support Oncol. 2012 Jul-Aug;10(4):155-9. doi: 10.1016/j.suponc.2011.10.006. Epub 2012 Jan 4.

PMID:
22222250
15.

Varicella zoster virus infections following allogeneic bone marrow transplantation: frequency, risk factors, and clinical outcome.

Koc Y, Miller KB, Schenkein DP, Griffith J, Akhtar M, DesJardin J, Snydman DR.

Biol Blood Marrow Transplant. 2000;6(1):44-9.

16.

Prophylactic role of long-term ultra-low-dose acyclovir for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation.

Kawamura K, Wada H, Yamasaki R, Ishihara Y, Sakamoto K, Ashizawa M, Sato M, Machishima T, Terasako K, Kimura S, Kikuchi M, Nakasone H, Yamazaki R, Kanda J, Kako S, Tanihara A, Nishida J, Kanda Y.

Int J Infect Dis. 2014 Feb;19:26-32. doi: 10.1016/j.ijid.2013.09.020. Epub 2013 Nov 6.

17.

Varicella zoster reactivation after hematopoietic stem cell transplant in children is strongly correlated with leukemia treatment and suppression of host T-lymphocyte immunity.

Vermont CL, Jol-van der Zijde EC, Hissink Muller P, Ball LM, Bredius RG, Vossen AC, Lankester AC.

Transpl Infect Dis. 2014 Apr;16(2):188-94. doi: 10.1111/tid.12180. Epub 2014 Jan 20.

PMID:
24438482
18.
19.

Clinical features and risk factors for developing varicella zoster virus dissemination following hematopoietic stem cell transplantation.

Umezawa Y, Kakihana K, Oshikawa G, Kobayashi T, Doki N, Sakamaki H, Ohashi K.

Transpl Infect Dis. 2014 Apr;16(2):195-202. doi: 10.1111/tid.12181. Epub 2014 Jan 20.

PMID:
24438510
20.

Varicella-zoster infection after allogeneic bone marrow transplantation: incidence, risk factors and prevention with low-dose aciclovir and ganciclovir.

Steer CB, Szer J, Sasadeusz J, Matthews JP, Beresford JA, Grigg A.

Bone Marrow Transplant. 2000 Mar;25(6):657-64.

Supplemental Content

Support Center